WeVote
Log In

Bill

Bill

HF 2930

Amyotrophic lateral sclerosis research funding provided, report required, appropriation cancelled, and money appropriated.

2025-2026 Regular Session Introduced by Mike Freiberg and 4 co-sponsors

Directs funding for ALS research in Minnesota with mandatory reporting on spending and outcomes, and clarifies how appropriations are managed and possible reallocation.

Introduction and first reading, referred to Higher Education Finance and Policy
#education-higher #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 2930

Summary of HF 2930 (2025-2026) – Minnesota

Overview

HF 2930 seeks to address amyotrophic lateral sclerosis (ALS) by directing funding for ALS research, establishing reporting requirements, and clarifying appropriations and related processes. The bill was introduced in the 2025-2026 session and referred to the Higher Education Finance and Policy committee. It has multiple co-sponsors.

Purpose and Intent

  • To support ALS research through targeted funding.
  • To require reporting related to the funded ALS research activities and outcomes.
  • To clarify the status of appropriations, including cancellation and reallocation provisions, and ensure money appropriated is used for the intended ALS research purposes.

Key Provisions (Proposed Provisions Based on Title and Summary)

Note: The following outlines reflect the bill’s stated focus as per its title and typical elements for this type of measure. Specific text may include additional details not listed here.

  1. ALS Research Funding

    • Establishes or designates funds for ALS research.
    • Aims to support scientific, clinical, or translational ALS research projects within Minnesota or by Minnesota institutions.
    • May authorize a specific appropriation amount or authorize appropriation in a future budget cycle, subject to legislative approval.

  2. Reporting Requirements

    • Requires a formal report on ALS research funding activities, including:
      • Allocation of funds (grants, contracts, or other expenditures).
      • Progress and outcomes of funded projects.
      • Milestones, timelines, and metrics for evaluating research progress.
      • Accountability mechanisms to ensure funds are used for their intended purpose.
    • Specifies recipients of reports (e.g., the legislature, a designated state department or commission, or a research oversight body).

  3. Appropriation and Cash Management

    • Addresses the status of appropriated funds, including potential cancellation and reappropriation provisions.
    • Clarifies conditions under which money appropriated for ALS research may be canceled or redirected, and the process for doing so.
    • Ensures funds are maintained for ALS research purposes and provides oversight to prevent misallocation.

Affected Parties and Stakeholders

  • ALS researchers and institutions (universities, hospitals, research centers) in Minnesota.
  • Minnesota state government and relevant funding and oversight agencies (e.g., higher education, health, and finance offices).
  • Individuals affected by ALS and patient advocacy groups may benefit from increased research activity and transparency in funding outcomes.
  • Legislators and budget policymakers who oversee appropriations and reporting requirements.

Procedural and Timeline Considerations

  • Status: Introduced and referred to the Higher Education Finance and Policy committee (as of March 27, 2025).
  • Next steps typically include committee hearings, potential amendments, committee passage, and eventual floor consideration by the Minnesota Legislature.
  • Any final enactment would require passage by both chambers and signature by the governor, with effective dates typically tied to the enacted bill or a specified implementation timeline.

Potential Impacts and Implications

  • Improved funding for ALS research in Minnesota, potentially accelerating scientific discoveries and therapeutic development.
  • Enhanced transparency through formal reporting on how funds are spent and what outcomes are achieved.
  • Clearer management of appropriations to prevent premature dissolution of funds dedicated to ALS research.
  • Possible long-term benefits for ALS patients through advancements in understanding, treatments, or care strategies.

If you would like, I can incorporate the exact fiscal details, reporting formats, or proposed amendments once the bill text is available, and provide a side-by-side with related Minnesota ALS initiatives or past ALS funding bills for context.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.